SCHEMBL2947874

SCHEMBL2947874

c1csc(-c2cnc3ccc(NCC4CC4)nn23)c1

nearest known ligand 0.61

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 8/20 0.61
FYN P06241 5/20 0.60
PIM2 Q9P1W9 1/20 0.59
IKBKB O14920 7/20 0.55
CHUK O15111 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2949833 0.82 PIM1 (0.71) PIM1FYNPIM2IKBKB
SCHEMBL15254325 0.81 FYN (0.68) PIM1FYN
SCHEMBL1053098 0.81 FYN (0.77) FYN
SCHEMBL2945291 0.81 FYN (0.59) PIM1FYNPIM2IKBKB
SCHEMBL19467039 0.81 FYN (0.52) FYN
SCHEMBL2943516 0.80 FYN (0.67) PIM1FYNPIM2IKBKBCHUK
SCHEMBL2947988 0.80 PIM1 (0.75) PIM1FYNPIM2IKBKBCHUK
SCHEMBL24736858 0.79 MKNK1 (0.69) PIM1FYN
SCHEMBL2947647 0.79 FYN (0.73) PIM1FYN
SCHEMBL15255014 0.79 FYN (0.63) FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7906512-B2 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases ALCON, INC. (CH) 2011-03-15 US disclosed
US-7906512-B2 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases ALCON, INC. (CH) 2011-03-15 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20100168116-A1 3,6-SUBSTITUTED IMIDAZOL[1,2-B]PYRIDAZINE ANALOGS FOR TREATING ALLERGIC AND INFLAMMATORY DISEASES ALCON, INC. (CH) 2010-07-01 US disclosed
US-20100168116-A1 3,6-SUBSTITUTED IMIDAZOL[1,2-B]PYRIDAZINE ANALOGS FOR TREATING ALLERGIC AND INFLAMMATORY DISEASES ALCON, INC. (CH) 2010-07-01 US disclosed
US-7713975-B1 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases ALCON, INC. (CH) 2010-05-11 US disclosed
US-7713975-B1 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases ALCON, INC. (CH) 2010-05-11 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168116-A1 3,6-SUBSTITUTED IMIDAZOL[1,2-B]PYRIDAZINE ANALOGS FOR TREATING ALLERGIC AND INFLAMMATORY DISEASES SYK, IRAK3, IRAK2 PIM1 588/4885FYN 34/4885PIM2 460/4885
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 PIM1 365/4885FYN 421/4885PIM2 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.